This announcement is a separate document:
三生国健：关于自愿披露公司重组抗IL-17A人源化单克隆抗体注射液（SSGJ-608）治疗中重度斑块状银屑病III期临床试验达到所有疗效终点的公告
Sunshine Guojian Pharmaceutical: Announcement regarding the voluntary disclosure of clinical trial results for the humanized anti-IL-17A monoclonal antibody injection (SSGJ-608) for the treatment of moderate to severe plaque psoriasis in Phase III, achieving all efficacy endpoints.
The translation is provided by third-party software.
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.